Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

RAD 301 shows strong imaging potential in pancreatic cancer

Monday, November 18, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has reported promising results for RAD 301, showcasing its strong imaging capabilities in pancreatic cancer. The company has received positive clinical updates across its programs, including the recent IND approval from the US FDA for a new therapeutic study targeting B7H3. This positions RAD 301 as a significant player in the oncology imaging space.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD 301 demonstrates strong imaging potential in pancreatic cancer.
  • Positive clinical updates across multiple programs.
  • Recent IND approval from the US FDA for a new therapeutic study.

Full Press Release Details

• Announcements
• Price Sensitive
• November 18, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• May 15, 2024
• Announcements
• July 2, 2024
• Announcements
• December 20, 2021
• Announcements
• December 15, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD 301 used for?

RAD 301 is used for imaging potential in pancreatic cancer.

What recent approvals has Radiopharm received?

Radiopharm received IND approval from the US FDA for a therapeutic study targeting B7H3.

What updates have been reported for RAD 301?

Radiopharm has reported positive clinical updates for RAD 301 across multiple programs.

Tags: RADX Viatris Investor Conferences Healthcare RAD 301 pancreatic cancer Radiopharm Theranostics FDA approval clinical updates
Last updated: Nov 18, 2024